-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Extrahepatic Bile Duct Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Extrahepatic Bile Duct Cancer Drug Details: Zanidatamab is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Docetaxel in Prostate Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Docetaxel in Prostate Cancer Drug Details: docetaxel (ATI-1123) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Metronidazole in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Metronidazole in Clostridioides difficile Infections (Clostridium difficile Associated Disease) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zunsemetinib in Psoriatic Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zunsemetinib in Psoriatic Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Zunsemetinib in Psoriatic Arthritis Drug Details:Zunsemetinib (ATI-450, CDD-450) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zunsemetinib in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zunsemetinib in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zunsemetinib in Rheumatoid Arthritis Drug Details: Zunsemetinib (ATI-450, CDD-450) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amylin Agonist Long Acting in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amylin Agonist Long Acting in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amylin Agonist Long Acting in Obesity Drug Details: Amylin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Photobac in Gliosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Photobac in Gliosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Photobac in GliosarcomaDrug Details:Photobac is under development for the treatment of recurrent glioblastoma multiforme,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nifurtimox in Refractory Medulloblastoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Nifurtimox in Refractory MedulloblastomaDrug Details:Nifurtimox is a nitrofuran derivative, acts as an antiprotozoal agent. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DO-1 in GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DO-1 in GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DO-1 in GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency)Drug Details:DO-1...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-932 in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-932 in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-932 in Generalized Anxiety Disorder (GAD) Drug Details: ABBV-932...